Effect of single-dose rituximab on primary glomerular diseases

Nephron - Clinical Practice

Volumn 117, Issue 2, 2011, Pages

  Sugiura, Hidekazu ^a   Takei, Takashi ^a   Itabashi, Mitsuyo ^a   Tsukada, Misao ^a   Moriyama, Takahito ^a   Kojima, Chiari ^a   Shiohira, Toshiharu ^a   Shimizu, Ari ^a   Tsuruta, Yuki ^a   Amemiya, Nobuyuki ^a   Ogawa, Tetsuya ^a   Uchida, Keiko ^a   Tsuchiya, Ken ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Primary glomerular disease; Rituximab

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CREATININE; CYCLOSPORIN A; CYPROHEPTADINE; INTERLEUKIN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; RITUXIMAB; TACROLIMUS;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; FOCAL GLOMERULONEPHRITIS; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SERUM; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955193837     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319656     Document Type: Article

References (26)

1. Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N: Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 2002;61:1801-1805.
2. Kranz B, Vester U, Büscher R, Wingen AM, Hoyer PF: Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol 2008;23:581-586.
3. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F: Rituximab treatment for severe steroidor cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008;23:1269-1279.
4. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K: Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009;24:1321-1328.
5. Hofstra JM, Deegens JK, Wetzels JF: Rituximab: effective treatment for severe steroiddependent minimal change nephrotic syndrome? Nephrol Dial Transplant 2007;22:2100-2102.
6. François H, Daugas E, Bensman A, Ronco P: Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 2007;49:158-161.
7. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (RIT) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2195.
8. Wong CF: Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculities: what is the current evidence? Nephrol Dial Transplant 2007;22:32-36.
9. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F: CD20: A target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005;4:526-531.
10. Smith GC: Is there a role for rituximab in the treatment of idiopathic childhood nephritic syndrome? Pediatr Nephrol 2007;22:893-898.
11. Kurosu N, Sugiura H, Iwasaki C, Asamiya Y, Kojima C, Moriyama T, Itabashi M, Tsukada M, Takei T, Ogawa T, Yoshida T, Uchida K, Tsuchiya K, Nitta K: Successful use of singledose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med 2009;48:1901-1904.
12. Sawara Y, Itabashi M, Kojima C, Tabata H, Kamei D, Kawanishi K, Moriyama T, Sugiura H, Tsukada M, Takei T, Ogawa T, Yoshida T, Arai J, Uchida K, Tsuchiya K, Nitta K: Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin Nephrol 2009;72:69-72.
13. van den Berg J, Weening JJ: Role of the immune system in the pathogenesis of the idiopathic nephrotic syndrome. Clin Sci 2004;107:125-136.
14. Grimbert P, Audard V, Valanciute A, Pawlak A, Lang P, Guellaën G, Sahali D: Abnormal RNA processing and altered expression of serine-rich proteins in minimal change nephrotic syndrome. Pediatr Res 2005;57:133-137.
15. Mansour H, Cheval L, Elalouf JM, Aude JC, Alyanakian MA, Mougenot B, Doucet A, Deschênes G: T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome. Kidney Int 2005;67:2168-2177.
16. Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, Martin PY: Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007;20:102-105.
17. Kimata H, Fujimoto M, Furusho K: Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome. Eur J Immunol 1995;25:1497-1501.
18. Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC: Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999;10:529-537.
19. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M: A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991;40:453-460.
20. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M: Rituximab treatment for post transplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005;20:1660-1663.
21. Pescovitz MD, Book BK, Sidner RA: Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006;354:1961-1963.
22. El-Firjani A, Hoar S, Karpinski J, Bell R, Deschenes MJ, Knoll GA: Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy. Nephrol Dial Transplant 2008;23:425.
23. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G: Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003;14:1851-1857.
24. Cohen CD, Calvaresi N, Armelloni S, Schmid H, Henger A, Ott U, Rastaldi MP, Kretzler M: CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 2005;18:328-333.
25. Holdsworth SR, Kitching AR, Tipping PG: Th1 and Th2 helper cell subsets affect patterns of injury and outcomes in glomerulonephrities. Kidney Int 1999;55:1198-1216.
26. Biancone L, Andres G, Ahn H, DeMartino C, Stamenkovic I: Inhibition of the CD40-CD40 ligand pathway prevents murine membranous glomerulonephritis. Kidney Int 1995;48:458-468.